NC
Nexthera Capital Portfolio holdings
AUM
$120M
1-Year Return
20.18%
This Quarter Return
+3.11%
1 Year Return
+20.18%
3 Year Return
+117.79%
5 Year Return
–
10 Year Return
–
AUM
$427M
AUM Growth
+$20M
(+4.9%)
Cap. Flow
+$16.3M
Cap. Flow
% of AUM
3.81%
Top 10 Holdings %
Top 10 Hldgs %
53.84%
Holding
57
New
18
Increased
15
Reduced
8
Closed
12
Top Buys
| 1 |
Exelixis
EXEL
|
$30.6M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
$19.3M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$16.5M |
| 4 |
Esperion Therapeutics
ESPR
|
$11.3M |
| 5 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
$9.23M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$21.7M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$21M |
| 3 |
SHPG
Shire pic
SHPG
|
$20.8M |
| 4 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$17.3M |
| 5 |
Heron Therapeutics
HRTX
|
$11.3M |
Sector Composition
| 1 | Healthcare | 91.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
VYNE Therapeutics
VYNE
$7.62M
| – | – |
-1,030
| Closed | -$2.79M |
|
52
SPDR S&P Biotech ETF
XBI
$5.39B
| – | – |
0
| – | – |
|
53
Xenon Pharmaceuticals
XENE
$3.02B
| – | – |
-379,071
| Closed | -$1.86M |
|
54
Q32 Bio
QTTB
$20.4M
| – | – |
-722
| Closed | -$243K |
|
|
LUMO
55
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| – | – |
0
| – | – |
|
|
CLVS
56
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – |
0
| – | – |
|
|
SHPG
57
DELISTED
Shire pic
SHPG
| – | – |
-139,543
| Closed | -$20.8M |
|